A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
published in: Journal for Immunotherapy of Cancer
date of publication: 2020-03-01
Cites articles 16
- 2015
Date
Title
Article - wd:Q90370695